A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 150, Issue 2, August 2018, Pages 247-252

John K. Chan, William Brady, Bradley J. Monk, Jubilee Brown, Mark S. Shahin, Peter G. Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L. Walker, David M. Gershenson,